neurons with red stoplasma were denser in sectors than the other neurons. Glutamate immunopositivity has detected in hippocampal neurons, neuropil, habenular nuclei and cortical tractus. Number of neurons were significantly less in morphine group compaired to controls and there were no significant difference between control and agmatine treated groups. Conclusion: According to the findings of the current study repeated morphine withdrawal syndrome can cause damage on learning-memory and glutamatergic system may play a role at least a part. Agmatine has a clear protective role on memory functions. Further research is necessary to understand the mechanism underlying.
Methods: Rats were trained in a touch screen chamber to learn the relationships between 4 different light signals on the screen and accompanied reward outcomes and punishments set up with different schedules, for one session of 30 min each day. Then, they were allowed for free choices out of 4 different light signals. Once animals showed a stabilized pattern of preference, they were given 7 days of either saline or cocaine IP injections (a single injection per day) followed by 2 weeks of withdrawal. Then, their preference of choice was re-tested in rGT chambers. Results: Depending upon their preference of choice, rats were separated as either risk-averse or risk-seeking groups. However, when they were exposed to cocaine, rats in the risk-averse group significantly changed their preference toward more disadvantageous choices. Conclusions: These results indicate that cocaine influences even different types of decision-making behavior as in gambling task, which is not directly relevant with obtaining cocaine itself, implying that they may aggravate pathological symptoms of bad choices, resulting in negative consequences, observed in the patients with behavioral addictions. Keywords: pathological gambling, cocaine, decision making, behavioral addiction
PM287
Mixtures of opioid receptor agonists and cannabinoid receptor agonists: enhanced antinociception without abuse liability 
Abstract
Mu opioid receptor agonists remain the drugs of choice for treating moderate-severe pain despite their well-documented adverse effects (constipation, respiratory depression, abuse). Kappa opioid receptor agonists also have antinociceptive effects although adverse effects (dysphoria, hallucinations) have precluded their use in the clinic. One strategy for reducing or avoiding the adverse effects of opioid receptor agonists (mu and possibly kappa) is to combine them with drugs that exert antinociceptive effects through nonopioid mechanisms. The need for much smaller doses of each drug in a drug mixture, to achieve the desired therapeutic effect, has the potential to avoid the adverse effects that occur with larger doses of either drug administered alone, thereby increasing the therapeutic window of both drugs. These studies used adult male rats to examine the antinociceptive effects of mu and kappa opioid receptor agonists, each administered alone and in combination with a cannabinoid receptor agonist. When administered alone (intraperitoneally), morphine (mu receptor agonist; 1.78-17.8 mg/kg), spiradoline (kappa receptor agonist; 1-32 mg/ kg), Δ 9 -tetrahydrocannabinol (THC; cannabinoid receptor agonist; 3.2-32 mg/kg), and CP55940 (cannabinoid receptor agonist; 0.032-1 mg/kg) increased tail withdrawal latency from 50 o C water in a dose-related manner. Mixtures of an opioid and a cannabinoid, in ratios of 3:1, 1:1, and 1:3, also increased tail withdrawal latency in a dose-related manner. The interaction for both mu (morphine) and kappa (spiradoline) receptor agonists with a cannabinoid receptor agonist was at least additive for all mixtures and greater than additive (synergistic) for some ratios of some mixtures. Together these results support the view that mixtures of opioids and nonopioids could provide significant therapeutic effects (for treating pain) in the absence
